John Libbey Eurotext

Outcome of vagus nerve stimulation for drug-resistant epilepsy: the first three years of a prospective Japanese registry Volume 19, issue 3, September 2017


  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4


1 Jichi Medical University, Tochigi
2 Yamabiko Medical Welfare Center, Kagoshima
3 Nishiisahaya Hospital, National Nagasaki Medical Center, Nagasaki
4 LivaNova
5 Kyoto University, Kyoto
6 National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
7 Nishi-Niigata Chuo National Hospital, Niigata
8 Minato Hospital, Aomori
9 Kinki University Hospital, Osaka
10 Toranomon Hospital, Tokyo
11 Nihon Kohden, Co. Ltd
12 Tokyo Women's Medical University, Tokyo
13 Epilepsy Center Bethel, Miyagi
14 International University of Health and Welfare, Fukuoka
15 Ministry of Health, Labour and Welfare, Tokyo
16 Seirei Hamamatsu General Hospital, Shizuoka, Japan
* Correspondence: Kensuke Kawai Department of Neurosurgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
a VNS Approval Committee of Japan
b VNS Consulting Board


Vagus nerve stimulation (VNS) is an established option of adjunctive treatment for patients with drug-resistant epilepsy, however, evidence for long-term efficacy is still limited. Studies on clinical outcomes of VNS in Asia are also limited. We report the overall outcome of a national, prospective registry that included all patients implanted in Japan.